Ophthalmologists' Awareness of Geographic Atrophy: An Italian Survey Including 365 Participants

Overview

Journal Eur J Ophthalmol

Specialty Ophthalmology

Date 2024 May 29

PMID 38809658

Authors

Alessandro Arrigo

Emanuela Aragona

Michele Allamprese

Maurizio Battaglia Parodi

Affiliations

Soon will be listed here.

Abstract

Purpose: Geographic atrophy (GA) is a severe complication of age-related macular degeneration (AMD) and leads to irreversible visual decline. To date, no effective treatment is available for GA patients. However, a number of new therapies have recently been approved and several others are in the pipeline. This rapid evolution of prospects for GA patients requires constant updating of ophthalmologists' understanding of GA and its management so as to provide the appropriate treatment. For this reason, Società Italiana di Scienze Oftalmologiche (S.I.S.O.) has designed a specific survey to gauge the position of Italian ophthalmologists in this regard.

Methods: The three hundred and sixty-five Italian ophthalmologists who agreed to take part received a seventeen-part questionnaire guaranteeing privacy and anonymity. The survey was compiled through an online portal and the results were sent directly to S.I.S.O. ETS. Two graders analyzed the data and recorded the results.

Results: The results showed a high level of self-assessed awareness and understanding of GA, as well as considerable willingness to further improve knowledge of the disease. Most of the participants claimed to have effective rules of conduct in place for managing GA patients, including prompt response, involving a high prevalence of nutraceutical prescriptions and lifestyle recommendations.

Conclusions: This survey provided an overview of how GA patients are managed in Italy. The Italian ophthalmology community appears to be ready to adopt the upcoming treatments for GA.

References

Sadda S, Guymer R, Holz F, Schmitz-Valckenberg S, Curcio C, Bird A . Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2017; 125(4):537-548. PMC: 11366072. DOI: 10.1016/j.ophtha.2017.09.028. View

Smith W, Assink J, Klein R, Mitchell P, Klaver C, Klein B . Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001; 108(4):697-704. DOI: 10.1016/s0161-6420(00)00580-7. View

. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000; 107(12):2224-32. PMC: 1470467. DOI: 10.1016/s0161-6420(00)00409-7. View

Bellmann C, Jorzik J, Spital G, Unnebrink K, Pauleikhoff D, Holz F . Symmetry of bilateral lesions in geographic atrophy in patients with age-related macular degeneration. Arch Ophthalmol. 2002; 120(5):579-84. DOI: 10.1001/archopht.120.5.579. View

Khan H, Aziz A, Sulahria H, Khan H, Ahmed A, Choudhry N . Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. Clin Ophthalmol. 2023; 17:321-327. PMC: 9892637. DOI: 10.2147/OPTH.S367089. View

Chakravarthy U, Augood C, Bentham G, de Jong P, Rahu M, Seland J . Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology. 2007; 114(6):1157-63. DOI: 10.1016/j.ophtha.2006.09.022. View

Shen L, Liu F, Grossetta Nardini H, Del Priore L . RECLASSIFICATION OF FUNDUS AUTOFLUORESCENCE PATTERNS SURROUNDING GEOGRAPHIC ATROPHY BASED ON PROGRESSION RATE: A Systematic Review and Meta-Analysis. Retina. 2019; 39(10):1829-1839. DOI: 10.1097/IAE.0000000000002480. View

Liao D, Grossi F, El Mehdi D, Gerber M, Brown D, Heier J . Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2019; 127(2):186-195. DOI: 10.1016/j.ophtha.2019.07.011. View

Agron E, Mares J, Chew E, Keenan T . Adherence to a Mediterranean Diet and Geographic Atrophy Enlargement Rate: Age-Related Eye Disease Study 2 Report 29. Ophthalmol Retina. 2022; 6(9):762-770. PMC: 9464676. DOI: 10.1016/j.oret.2022.03.022. View

10.

Castro-Castaneda C, Altamirano-Lamarque F, Ortega-Macias A, Santa Cruz-Pavlovich F, Gonzalez-De la Rosa A, Armendariz-Borunda J . Nutraceuticals: A Promising Therapeutic Approach in Ophthalmology. Nutrients. 2022; 14(23). PMC: 9740859. DOI: 10.3390/nu14235014. View

11.

Kaiser P, Karpecki P, Regillo C, Baumal C, Ryan E, Ip M . Geographic Atrophy Management Consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment. BMJ Open Ophthalmol. 2023; 8(1). PMC: 10603481. DOI: 10.1136/bmjophth-2023-001395. View

12.

Wang J, Mitchell P, Smith W, Cumming R . Bilateral involvement by age related maculopathy lesions in a population. Br J Ophthalmol. 1999; 82(7):743-7. PMC: 1722690. DOI: 10.1136/bjo.82.7.743. View

13.

Khanani A, Patel S, Staurenghi G, Tadayoni R, Danzig C, Eichenbaum D . Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023; 402(10411):1449-1458. DOI: 10.1016/S0140-6736(23)01583-0. View

14.

Richard A, Duker J, Reichel E . Geographic atrophy: where we are now and where we are going. Curr Opin Ophthalmol. 2021; 32(3):247-252. DOI: 10.1097/ICU.0000000000000763. View

15.

Boyer D, Schmidt-Erfurth U, van Lookeren Campagne M, Henry E, Brittain C . THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET. Retina. 2016; 37(5):819-835. PMC: 5424580. DOI: 10.1097/IAE.0000000000001392. View

16.

Deng Y, Qiao L, Du M, Qu C, Wan L, Li J . Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022; 9(1):62-79. PMC: 8720701. DOI: 10.1016/j.gendis.2021.02.009. View

17.

Holz F, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl H, Schmitz-Valckenberg S . Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007; 143(3):463-72. DOI: 10.1016/j.ajo.2006.11.041. View

18.

Lindblad A, Lloyd P, Clemons T, Gensler G, Ferris 3rd F, Klein M . Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009; 127(9):1168-74. PMC: 6500457. DOI: 10.1001/archophthalmol.2009.198. View

19.

Loewenstein A, Trivizki O . Future perspectives for treating patients with geographic atrophy. Graefes Arch Clin Exp Ophthalmol. 2022; 261(6):1525-1531. PMC: 10198833. DOI: 10.1007/s00417-022-05931-z. View

20.

Rein D, Wittenborn J, Burke-Conte Z, Gulia R, Robalik T, Ehrlich J . Prevalence of Age-Related Macular Degeneration in the US in 2019. JAMA Ophthalmol. 2022; 140(12):1202-1208. PMC: 9634594. DOI: 10.1001/jamaophthalmol.2022.4401. View